Hepatitis C Virus

Dosing complete in phase 1a study of oral HCV protease inhibitor for hepatitis C

Published in Hepatitis Weekly, October 4th, 2004

Vertex Pharmaceuticals Incorporated (VRTX) has successfully completed the dosing portion of a phase 1a clinical trial for VX-950, an investigational oral protease inhibitor for the treatment of hepatitis C virus (HCV) infection.

The study, involving 35 healthy volunteers and conducted in Europe, was designed to assess safety, tolerability and pharmacokinetics in escalating, single doses of VX-950.

Based on the results from this study and preclinical studies, the company expects to begin a phase 1b clinical study of VX-950 in HCV-infected patients by the end of the year.

In the phase 1a study, single doses ranging from 25 mg to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-10-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry